HIV drug resistance study for newly diagnosed adults
Part of Immune system & allergy, Infections clinical trials.
This study looks at HIV in people who have just been diagnosed. It checks for drug resistance (whether the virus is resistant to certain medicines) and how the virus spreads, which can help doctors choose the best treatment for you and others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You were recently diagnosed with HIV (confirmed by a lab test).
- You have never taken regular HIV medications (but taking PrEP or emergency PEP is allowed).
- You have a test result called a 'resistance genotype' (a lab test that checks how the virus responds to drugs).
- You do not object to your health data being used for this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an observational study that follows people to better understand how HIV and other infections (like sexually transmitted infections) happen and change over time. It may help researchers improve prevention and care, but it is mainly for monitoring rather than testing a new treatment.
This study tests a new injectable drug (VH4011499) for safety and how the body processes it. It's for healthy adults without HIV, and participants will get either the study drug or a placebo (an inactive shot).
This study enrolls people whose HIV infection is very recent or newly diagnosed (within the last few months). The researchers want to better understand early stages of HIV to improve how doctors identify and track new infections.
This is an observational study (not a new drug) that tracks how living with HIV can change over time in different treatment situations. It may help researchers understand long-term effects of the modern “protease inhibitor era” and improve future care.
This study tests a new long-acting medicine that may help prevent HIV. It is given as an injection, and the study checks how safe it is and how it works in healthy volunteers.
This trial tests a new type of medicine that aims to wake up HIV hiding in your body's cells by targeting a viral protein called Tat. The goal is to help find a way to clear the virus completely.
Hear when a new HIV Seropositivity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.